M. Bagot

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 641 citations · Full text

Immunodeficiencies, Immunology, Clinical End Points +17

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 621 citations · Full text

Cutaneous T-cell Lymphoma, Lymphoid Neoplasia, Medicine +6

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 569 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer et al. · Journal of Clinical Oncology · 2015 · 407 citations · Full text

Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells

Amal Nassif, Armand Bensussan, Laurence Boumsell et al. · Journal of Allergy and Clinical Immunology · 2004 · 401 citations

Inflammation, Toxic Epidermal Necrolysis, Immunotoxicology +7